Skip to main content
. 1999 Jun 8;96(12):6879–6884. doi: 10.1073/pnas.96.12.6879

Table 1.

Proportions (in %) of Vδ1 γδ T cells of all γδ T cells in tumors positive or negative for MICA/B and of γδT cells (in %) of CD3+ T cells

Tumor mAb 6D4 % γδT cells % Vδ1 γδ cells
CT-001-97 + 3 80
CT-046-98 + 15 46
CT-183-73 + 7 67
BT-046-99 2 25
BT-086-22 3 40
BT-086-38 2 21
BT-140-73 3 9
BT-183-26 1 10
BT-183-43 4 20
BT-183-76 + 4 51
BT-238-29 + 16 100
LT-086-36 2 2
LT-086-49 2 2
LT-140-26 + 2 60
LT-140-66 + 1 55
OT-183-83 + 2 80
OT-183-93 + 2 51
OT-238-01 + 4 35
PT-140-63 + 6 65
PT-183-87 2 20
PT-391-97 + 10 55
RT-046-29 + 4 70

Representative examples for tumor cell suspensions positive or negative for binding of mAb 6D4 are shown in Fig. 1. The frequencies of Vδ1 γδ T cells of all γδ T cells in MICA/B+ tumors were statistically significantly higher (P < 0.0001, Wilcoxon rank-sum test) as compared with the tumors that were MICA/B. All samples were positive for binding of mAb W6/32 (anti-HLA-A, -B, and -C). Examined were carcinomas of colon (CT), breast (BT), lung (LT), ovary (OT), prostate (PT), and renal cell (RT).